; and (ii) the date on which the data or information becomes available to the sponsor. (C) Exceptions The disclosure requirement in subparagraph (A) does not apply with respect to— (i) a trade secret or confidential commercial or financial information as defined in section 20.61 of title 21, Code of Federal Regulations (or successor regulations); or (ii) personally identifiable information. (3) Disclosure by HHS (A) In general Subject to subparagraph (B), the Secretary shall— (i) not later than 10 days after the Food and Drug Administration authorizes the emergency use of a covered product under section 564 of the Federal Food, Drug, and Cosmetic Act or approves or licenses a covered product under section 505 of such Act or section 351 of this Act, disclose to the public, in an easily accessible location on the website of the Department of Health and Human Services, all data and information required by paragraph (2) to be disclosed by the sponsor of the product; and (ii) not later than 30 days after receiving any additional such data and information, so disclose such data and information. (B) Exception The disclosure requirement in subparagraph (A) does not apply with respect to data and information exempted from disclosure by paragraph (2)(C). (4) Enforcement against sponsors for failure to disclose (A) Exclusion from definition of covered countermeasure Notwithstanding subsection (i)(1), a covered product is deemed to be excluded from the definition of a covered countermeasure for purposes of the provisions of this section (other than this subsection) and section 319F–4 if— (i) the covered product is administered on or after the date of enactment of the Consumer Vaccine Safety and Protection Act of 2023